TriangleNCT02186873 · OUTCOME
Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) at Week 16
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- Units on Scale
- Interval / dispersion
- Standard Deviation
- Time frame
- Baseline and Week 16
What was measured
The ASQoL is a self-administered health-related quality of life (HRQOL) instrument. It consists of 18 items requesting a Yes or No response to questions related to the impact of the disease/condition (including pain) on sleep, mood, motivation, ability to cope, activities of daily living, independence, relationships, and social life. A score of 1 is given to a response of "yes" on each item and all item scores are summed to a total score with a range of 0 to 18. Higher scores indicate worse HRQOL.
Analysis population: FAS included all participants who were randomized in the study. Here, 'N' (Number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.
Groups in this outcome
Group 1: Placebo Then Golimumab
Participants received placebo intravenous (IV) infusions at Weeks 0, 4, and 12. At Week 16 participants were crossed over to golimumab and received IV golimumab 2 mg/kg infusions at Weeks 16, 20, and every 8 weeks (q8w) thereafter through Week 52.
Group 2: Golimumab
Participants received IV golimumab 2 mg/kg infusion at Weeks 0, 4 and then q8w thereafter through Week 52. Participants received a placebo infusion at Week 16 to maintain the treatment blind.
| Group | Source count |
|---|---|
| Group 1: Placebo Then Golimumab | 98 |
| Group 2: Golimumab | 104 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Group 1: Placebo Then Golimumab | -1.8 | 4.57 | Not reported | Not reported | Not reported |
| Group 2: Golimumab | -5.4 | 5.01 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 4.57
- value
- -1.8
- group Id
- OG001
- spread
- 5.01
- value
- -5.4
- denoms
- counts
- group Id
- OG000
- value
- 98
- group Id
- OG001
- value
- 104
- units
- Participants
- description
- The ASQoL is a self-administered health-related quality of life (HRQOL) instrument. It consists of 18 items requesting a Yes or No response to questions related to the impact of the disease/condition (including pain) on sleep, mood, motivation, ability to cope, activities of daily living, independence, relationships, and social life. A score of 1 is given to a response of "yes" on each item and all item scores are summed to a total score with a range of 0 to 18. Higher scores indicate worse HRQOL.
- dispersion Type
- Standard Deviation
- groups
- description
- Participants received placebo intravenous (IV) infusions at Weeks 0, 4, and 12. At Week 16 participants were crossed over to golimumab and received IV golimumab 2 mg/kg infusions at Weeks 16, 20, and every 8 weeks (q8w) thereafter through Week 52.
- id
- OG000
- title
- Group 1: Placebo Then Golimumab
- description
- Participants received IV golimumab 2 mg/kg infusion at Weeks 0, 4 and then q8w thereafter through Week 52. Participants received a placebo infusion at Week 16 to maintain the treatment blind.
- id
- OG001
- title
- Group 2: Golimumab
- param Type
- MEAN
- population Description
- FAS included all participants who were randomized in the study. Here, 'N' (Number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.
- reporting Status
- POSTED
- time Frame
- Baseline and Week 16
- title
- Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) at Week 16
- type
- SECONDARY
- unit Of Measure
- Units on Scale
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice